Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis

Background and Aim:  The administration of pravastatin to patients with cholestatic liver disease has suggested the potential of the drug with regard to reducing raised plasma cholesterol and bile acid levels. Information about the mechanisms associated with this effect is lacking. Thus, the aim of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2011-10, Vol.26 (10), p.1544-1551
Main Authors: Kolouchova, Gabriela, Brcakova, Eva, Hirsova, Petra, Sispera, Ludek, Tomsik, Pavel, Cermanova, Jolana, Hyspler, Radek, Slanarova, Martina, Fuksa, Leos, Lotkova, Halka, Micuda, Stanislav
Format: Article
Language:English
Subjects:
Animals
bile acids
Bile Acids and Salts - metabolism
bile duct obstruction
Biological and medical sciences
Cholestasis - drug therapy
Cholestasis - genetics
Cholestasis - metabolism
cholesterol
Cholesterol - metabolism
Chronic Disease
Disease Models, Animal
Gastroenterology. Liver. Pancreas. Abdomen
Gene Expression Regulation, Enzymologic - drug effects
Homeostasis
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Liver - drug effects
Liver - metabolism
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Membrane Transport Proteins - genetics
Membrane Transport Proteins - metabolism
nuclear receptors
Other diseases. Semiology
Permeability
pravastatin
Pravastatin - pharmacology
Rats
Rats, Wistar
RNA, Messenger - metabolism
Time Factors
Transcription Factors - genetics
Transcription Factors - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim:  The administration of pravastatin to patients with cholestatic liver disease has suggested the potential of the drug with regard to reducing raised plasma cholesterol and bile acid levels. Information about the mechanisms associated with this effect is lacking. Thus, the aim of the present study is to evaluate pravastatin effects on the liver bile acid and cholesterol homeostasis in healthy and cholestatic rats. Methods:  Control sham‐operated and reversibly bile duct‐obstructed (BDO) rats were treated with pravastatin (1 or 5 mg/kg) or the vehicle alone for 7 days after surgery. Results:  Lower doses of pravastatin reduced bile acid plasma concentrations in cholestatic animals. The effect was associated with reduced liver mRNA expression of Cyp7a1, Cyp8b1, Mrp2, Ugt1a1 and the increased expression of Bsep. In addition, BDO‐induced increase in the liver content of cholesterol was normalized by pravastatin. The change was accompanied by the reduced liver expression of Hmg‐CoA reductase, LDL receptor, and Acat2, and induced the expression of Abca1 and Mdr2. These changes corresponded with the upregulation of nuclear receptors LXRα and PPARα, and the downregulation of FXR, CAR, SREBP‐2 and HNF1α. High doses of pravastatin lacked any positive effects on bile acids and cholesterol homeostasis, and blocked bile formation through the reduction of the biliary excretion of bile acids. Conclusions:  Pravastatin rendered a positive reduction in BDO‐induced increases in plasma bile acid concentrations and cholesterol liver content, mainly through the transcriptionally‐mediated downregulation of genes involved in the synthesis of these compounds in the liver.
ISSN:0815-9319
1440-1746
DOI:10.1111/j.1440-1746.2011.06748.x